Login / Signup

COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.

Nicolas VuilleumierMarcin KrawczykWiktor SmykFrank LammertAgostino Di Ciaula
Published in: European journal of clinical investigation (2020)
NAFLD can play a role in the outcome of COVID-19 illness due to frequent association with comorbidities. Initial evidences suggest that increased liver fibrosis in NAFLD might affect COVID-19 outcome. In addition, long-term monitoring of post-COVID-19 NAFLD patients is advisable, to document further deterioration of liver damage. Further studies are required in this field.
Keyphrases
  • coronavirus disease
  • sars cov
  • liver fibrosis
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • prognostic factors